Levosimendan Eql Pharma (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractility without increasing intracellular calcium. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers both preload and afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The product is supplied as a sterile solution for intravenous infusion, and the exact infusion rate and duration are set by the treating physician.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative for acute inotropic support is dobutamine, a β‑adrenergic agonist that increases intracellular calcium. Levosimendan enhances contractility without raising calcium levels and adds vasodilatory effects, which can result in a more favorable hemodynamic profile and lower risk of tachyarrhythmias compared with dobutamine.

Levosimendan Eql Pharma should be stored at ambient temperature, below 25 °C, in its original container. Protect the solution from direct light, moisture and extreme temperatures. Do not freeze the product, and inspect the vial for particulate matter before use.

The product is administered as an intravenous infusion. After reconstitution, a loading dose may be given over a short period followed by a continuous maintenance infusion, as directed by the prescribing clinician. Administration is performed under continuous cardiac and hemodynamic monitoring.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and allergic reactions such as anaphylaxis. Continuous monitoring of blood pressure, heart rhythm and cardiac biomarkers is essential to detect these events promptly and intervene as needed.

Levosimendan is contraindicated in patients with severe hypotension (systolic blood pressure markedly low) and in those with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with significant renal or hepatic impairment, where dose adjustment may be required.